Procyrion, Inc. Wins Best Overall Medical Device Product in 2018 MedTech Breakthrough Awards

Press Release

HOUSTON, TEXAS (July 2, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, today announced that its AortixTM device won the MedTech Breakthrough Award for "Best Overall Medical Device Product."

MedTech Breakthrough is an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market. Award recipients are honored for their innovation, hard work and success in a range of categories, including Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data, and more.

"We are honored to win this innovation award and to be recognized alongside such esteemed healthcare technology leaders," said Procyrion CEO, Ben Hertzog. “Our talented team has been working extremely hard to bring this important technology to the clinic.  We intend to provide cardiologists with the first tool to address cardiorenal syndrome in chronic heart failure patients.”

Procyrion’s novel technology, Aortix, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically to address cardiorenal syndrome in chronic heart failure patients who are failing medical therapy, but not sick enough for risky surgical interventions like heart transplants or LVADs. The unique placement of the small but powerful micropump in the descending thoracic aorta is intended to simultaneously unload the heart and support the kidneys by accelerating native blood flow in the aorta.

This year's MedTech Breakthrough Awards program attracted more than 3,000 nominations from around the world. All nominations were evaluated by an independent panel of experts within the medical and health industry.



Procyrion Inc., headquartered in Houston, Texas, is developing catheter-based circulatory support technologies to address the significant unmet clinical need in the large chronic heart failure population.  Aortix is not approved for sale in any geography. 

PR Contact:

Dana Summers

Penman PR


Read More